A Randomized, Single-dose, Open-label, Single-center, Crossover Study to Assess the Fed- and Fasted State Bioequivalence of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2017
Price : $35 *
At a glance
- Drugs Dapagliflozin/metformin (Primary) ; Dapagliflozin/metformin/saxagliptin (Primary) ; Dapagliflozin; Metformin; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 27 Nov 2017 Status changed from active, no longer recruiting to completed.
- 13 Nov 2017 Planned End Date changed from 28 Nov 2017 to 27 Nov 2017.
- 13 Nov 2017 Planned primary completion date changed from 28 Nov 2017 to 27 Nov 2017.